Virginia Drug Discovery Consortium
The Virginia Drug Discovery Consortium (VaDDC) has a threefold mission:
To promote the growth and advancement of drug discovery and development programs at universities and research institutes within Virginia, particularly through inter-institutional collaboration.
To help the pharmaceutical industry bring life-saving and quality of life solutions to patients through innovative collaborations with Virginia’s best and brightest researchers.
To promote and enhance the attractiveness of Virginia as an environment for pharmaceutical and biotech companies.
VirginiaDrugDiscoveryRx: Emerging Targets, Technologies, and Therapeutics for Cancer and Neuroscience
The VaDDC Executive Committee is pleased to announce the VirginiaDrugDiscoveryRx: Emerging Targets, Technologies, and Therapeutics for Cancer and Neuroscience meeting will be held at the Hotel Roanoke – May 21, 22, 2019.
- The VaDDC strives to promote the vibrant drug discovery and development efforts at the research institutions in the state of Virginia.
- VirginiaDrugDiscoveryRx was a resounding success with 146 attendees from academia, the private sector and government. The meeting showcased the dynamic drug discovery environment in the state of Virginia and focused on the development of public-private drug discovery partnerships, which are foundational to translational research.
- The recently held VirginiaDrugDiscoveryRx was the 3rd annual meeting organized by the Virginia Drug Discovery Consortium, and followed the highly successful VirginiaBrainRx (2016, Virginia Commonwealth University, Richmond, VA) and VirginiaCancerRx (2017, University of Virginia, Charlottesville, VA).
Thank you to our sponsors whose participation in the recent VirginiaDrugDiscoveryRx Symposium held at George Mason University, June 25-26, 2018 was key to the meeting’s success.
Virginia Tech Center for Drug Discovery Researcher receives $1.2 million to find Compounds to Treat Fatty Liver Disease
Webster Santos (VT), Kyle Hoehn (UVA): A grant from the VBHRC, known as Virginia Catalyst along with matching funds from Continuum Biosciences, a company they co-founded will fund research to fight a liver condition that can lead to liver cancer. Read more ...read more
Frank Gupton receives a $25M award from the Gates foundation for the "Medicines for All" Initiative" The Bill & Melinda Gates Foundation has awarded the Virginia Commonwealth University School of Engineering $25 million to create the Medicines for All Institute, a...read more
John Lazo (VaDDC, Univ. of Virginia Pharmacology), David Kingston (VaDDC, Virginia Tech Chemistry) and Thomas Loughran (Director, Univ. of Virginia Cancer Center) were interviewed by Charlottesville’s CBS affiliate regarding Virginia Drug Discovery Consortium’s 2017...read more
Want to work with us?
If you are interested in supporting this initiative, please contact us.